

## ORIGINAL RESEARCH ARTICLE

# Ambulatory blood pressure and long-term risk for atrial fibrillation

Valérie Tikhonoff,<sup>1</sup> Tatiana Kuznetsova,<sup>2</sup> Lutgarde Thijs,<sup>2</sup> Nicholas Cauwenberghs,<sup>2</sup> Katarzyna Stolarz-Skrzypek,<sup>3</sup> Jitka Seidlerová,<sup>4</sup> Sofia Malyutina,<sup>5</sup> Natasza Gilis-Malinowska,<sup>6</sup> Ewa Swierblewska,<sup>6</sup> Kalina Kawecka-Jaszcz,<sup>3</sup> Jan Filipovský,<sup>4</sup> Krzysztof Narkiewicz,<sup>6</sup> Gregory Y H Lip,<sup>7</sup> Edoardo Casiglia,<sup>1</sup> Jan A Staessen,<sup>2</sup> the European Project On Genes in Hypertension (EPOGH) Investigators

► Additional material is published online only. To view please visit the journal online (<http://dx.doi.org/10.1136/heartjnl-2017-312488>).

For numbered affiliations see end of article.

## Correspondence to

Dr Tatiana Kuznetsova, Research Unit Hypertension and Cardiovascular Epidemiology, KU Leuven Department of Cardiovascular Sciences, University of Leuven, Leuven 3000, Belgium; [tatiana.kouznetsova@kuleuven.be](mailto:tatiana.kouznetsova@kuleuven.be)

VT and TK contributed equally.

Received 26 September 2017  
Revised 11 December 2017  
Accepted 12 December 2017  
Published Online First  
9 February 2018

## ABSTRACT

**Objective** Data on the contribution of ambulatory blood pressure (ABP) components to the risk of developing atrial fibrillation (AF) are limited. We prospectively tested the hypothesis that ABP may represent a potentially modifiable risk factor for the development of AF in a European population study. **Methods** We recorded daytime blood pressure (BP) in 3956 subjects randomly recruited from the general population in five European countries. Of these participants, 2776 (70.2%) underwent complete 24-hour ABP monitoring. Median follow-up was 14 years. We defined daytime systolic BP load as the percentage BP readings above 135 mm Hg. The incidence of AF was assessed from ECGs obtained at baseline and follow-up and from records held by general practitioners and/or hospitals.

**Results** Overall, during 58 810 person-years of follow-up, 143 participants experienced new-onset AF. In adjusted Cox models, each SD increase in baseline 24 hours, daytime and night-time systolic BP was associated with a 27% ( $P=0.0056$ ), 22% ( $P=0.023$ ) and 20% ( $P=0.029$ ) increase in the risk for incident AF, respectively. Conventional systolic BP was borderline associated with the risk of AF (18%;  $P=0.06$ ). As compared with the average population risk, participants in the lower quartile of daytime systolic BP load (<3%) had a 51% ( $P=0.0038$ ) lower hazard for incident AF, whereas in the upper quartile (>38%), the risk was 46% higher ( $P=0.0094$ ).

**Conclusions** Systolic ABP is a significant predictor of incident AF in a population-based cohort. We also observed that participants with a daytime systolic BP load >38% had significantly increased risk of incident AF.

## INTRODUCTION

Atrial fibrillation (AF) is the most common cardiac arrhythmia in the general population, and its incidence is substantially increasing with the ageing populations.<sup>1</sup> Over 50 years of observation in the Framingham Heart Study, the age-adjusted prevalence of AF increased from 20.4 to 96.2 cases per 1000 person-years in men and from 13.7 to 49.4 cases per 1000 person-years in women.<sup>2</sup> Globally, the estimated number of individuals with AF in

2010 was 33.5 million,<sup>1</sup> and the prevalence of AF is expected to significantly rise in the coming years.<sup>3,4</sup> These data underscore the need for a better understanding of the complexity of AF determinants and for improvement of AF prevention strategies related to the specific modifiable risk factors.

It is well established that hypertension is one of the most important contributors to the burden of AF and can potentially explain more than one-fifth of all AF cases, and nearly one quarter, if a borderline high blood pressure (BP) was also included.<sup>5</sup> The importance of individual BP components on conventional BP in the development of AF has also been investigated.<sup>6–9</sup> In the Framingham Heart Study,<sup>10</sup> participants belonging to the trajectory groups with persistently elevated systolic BP and longer antihypertensive treatment had an increased 15-year risk of incident AF as compared with participants who remained normotensive throughout the longitudinal data collection. The researchers suggested that each trajectory group of systolic and diastolic BP may have unique properties that require further investigation.<sup>10</sup>

Our previous study based on a large population database from four countries has shown that daytime ambulatory BP (ABP) was superior to conventional BP in the predicting of cardiovascular events and risk stratification.<sup>11</sup> However, to our knowledge, only two small studies in patients with hypertension<sup>8</sup> and in general population<sup>12</sup> have investigated the relative significance of different ABP components in predicting new-onset AF. Accordingly, we prospectively tested the hypothesis that ABP measurement is a potentially modifiable risk factor for incident AF in general population randomly recruited in five European countries.

## METHODS

### Study population

Recruitment for the Flemish Study on Environment, Genes and Health Outcomes (FLEMENGHO) started in 1985.<sup>13</sup> A random sample of the households living in a geographically defined area of Northern Belgium was investigated with the goal to recruit an equal number of participants in each of six subgroups by sex and age. The European Project on Genes in Hypertension (EPOGH)



**To cite:** Tikhonoff V, Kuznetsova T, Thijs L, *et al.* *Heart* 2018;**104**:1263–1270.

investigators applied the same recruitment and examination protocols, questionnaires and follow-up procedures, as used in FLEMENGHO.<sup>14</sup>

Online supplementary table S1 lists detailed information on participation rate, enrolment and duration of follow-up of the included cohorts. We measured the conventional and ABP at baseline in 4314 participants, including 2904 FLEMENGHO and 1410 EPOGH participants. We excluded individuals if they were younger than 18 years (n=304) or if they had <10 daytime BP readings (n=38). After exclusion of 16 subjects with AF at baseline, the number of subjects totaled 3956. Of these, 2776 (70.2%) participants underwent complete 24-hour ABP monitoring including both daytime and night-time periods.

### Conventional and ABP measurement

At the participants' homes, trained observers measured the conventional BP with a mercury sphygmomanometer, using the appropriate cuff size, with participants in the sitting position. The conventional BP was the average of five consecutive readings. We programmed portable BP monitors to obtain daytime ABP readings at 15 min or, in the FLEMENGHO study, 20 min intervals from 08:00 to 22:00 and at 45 min at night.<sup>11 15</sup> The used devices implemented an oscillometric technique (SpaceLabs 90207; Spacelabs, Washington, USA, and The Takeda TM2430; A&D, Tokyo, Japan). Daytime and night-time was defined as the intervals ranging from 10:00 hours to 20:00 hours and

from 00:00 hours to 06:00 hours, respectively.<sup>16</sup> We weighted the individual means of the ABP by the time interval between successive readings. Recordings with less than 10 daytime and/or five night-time readings were not considered for analysis. For both conventional and ABP measurements, pulse pressure was the difference between the systolic and diastolic BP.

In line with current guidelines for the diagnosis and management of hypertension,<sup>17</sup> we defined hypertension as a conventional BP equal to or exceeding 140 mm Hg systolic or 90 mm Hg diastolic or as use of antihypertensive drugs. Corresponding thresholds for daytime ambulatory hypertension were 135 mm Hg systolic and 85 mm Hg diastolic daytime BP. We defined daytime systolic BP load as the percentage BP readings above the cut-off point as defined by the European Society of Hypertension (135 mm Hg). Normotension was a consistently untreated normal BP on both conventional and ambulatory measurements. White-coat hypertension was a raised conventional BP in the presence of a normal daytime BP. Masked hypertension was an elevated ABP with normal conventional BP. Sustained hypertension was a consistently elevated BP on both conventional and ambulatory measurements. Patients on antihypertensive drug treatment were classified as having sustained hypertension.

### Other measurements

In all centres, at the enrolment visit and at follow-up, a standardised questionnaire was used to collect detailed information

**Table 1** Clinical baseline characteristics of the study participants with and without incident atrial fibrillation

Characteristics	No AF	Incident AF	P value*
Participants with available daytime ABPM	n=3813	n=143	
Duration of follow-up (years)	14.0 (10.9 to 19.1)	12.0 (7.3 to 16.1)	
Clinical features			
Female, n (%)	1989 (52.2)	61 (42.7)	0.026
Age (years)	42.5±14.9	59.2±11.3	<0.0001
Body mass index (kg/m <sup>2</sup> )	25.5±4.5	28.1±4.8	<0.0001
Questionnaire data			
Tobacco use, n (%)	1065 (27.9)	28 (19.6)	0.027
Alcohol intake ≥5 g/day, n (%)	1079 (28.3)	29 (20.3)	0.036
Antihypertensive treatment, n (%)	552 (14.5)	48 (33.6)	<0.0001
Diabetes mellitus, n (%)	114 (3.0)	10 (7.0)	0.0070
History of CV diseases, n (%)	287 (7.5)	33 (23.1)	<0.0001
Biochemical data			
Serum total cholesterol (mmol/L)	5.32±1.12	5.76±1.23	0.0005
Participants with complete 24-hour ABPM	n=2665	n=111	
Duration of follow-up (years)	13.5 (9.2 to 22.7)	13.0 (7.3 to 17.1)	
Clinical features			
Female, n (%)	1399 (52.5)	48 (43.2)	0.056
Age (years)	43.1±15.0	59.0±10.4	<0.0001
Body mass index (kg/m <sup>2</sup> )	25.6±4.5	28.0±4.9	<0.0001
Questionnaire data			
Tobacco use, n (%)	747 (28.0)	22 (19.8)	0.058
Alcohol intake ≥5 g/day, n (%)	736 (27.6)	22 (19.8)	0.071
Antihypertensive treatment, n (%)	414 (15.5)	38 (34.2)	<0.0001
Diabetes mellitus, n (%)	89 (3.3)	7 (6.3)	0.094
History of CV diseases, n (%)	233 (8.7)	27 (24.3)	<0.0001
Biochemical data			
Serum total cholesterol (mmol/litre)	5.34±1.15	5.85±1.16	<0.0001

Values are arithmetic mean±SD or number of subjects (%) or median (IQR). P values are for differences between two groups. ABPM, ambulatory blood pressure monitoring; AF, atrial fibrillation; CV, cardiovascular.

**Table 2** Conventional and ambulatory blood pressures and heart rate of the study participants with and without incident atrial fibrillation

Characteristics	No AF	Incident AF	P value*
Participants with available daytime ABP	n=3813	n=143	
Conventional blood pressure (mm Hg)*			
Systolic	124.6±16.3	135.1±20.1	<0.0001
Diastolic	77.2±10.7	80.2±12.2	<0.0001
Pulse pressure	47.4±11.8	54.9±15.7	<0.0001
Conventional heart rate (bpm)	70.7 ±10.2	68.9±10.3	0.036
Daytime blood pressure (mm Hg)			
Systolic	124.9±11.6	130.3±13.0	<0.0001
Diastolic	77.4±8.1	79.3±8.9	0.0006
Pulse pressure	47.5±7.8	51.0±9.7	<0.0001
Systolic blood pressure load, daytime (%)	13.3 (3.23–36.8)	26.7 (11.8–57.1)	<0.0001
Daytime heart rate (bpm)	78.4±10.9	75.4±10.6	0.0003
Participants with complete 24-hour ABP	n=2665	n=111	
Conventional blood pressure (mm Hg)*			
Systolic	125.4±16.8	136.0±20.7	<0.0001
Diastolic	77.7±10.8	80.8±12.3	0.011
Pulse pressure	47.7±11.9	55.1±16.4	<0.0001
Conventional heart rate (bpm)	72.2±10.2	70.2±10.6	0.043
Mean 24-hour blood pressure (mm Hg)			
Systolic	119.1±11.3	124.7±12.5	<0.0001
Diastolic	72.0±7.6	74.4±8.6	0.0014
Pulse pressure	47.1±7.4	50.3±8.9	0.0003
Mean 24-hour heart rate (bpm)	72.8±8.8	70.8±9.4	0.023
Daytime blood pressure (mm Hg)			
Systolic	125.4±12.0	130.4±12.8	<0.0001
Diastolic	77.8±8.2	79.3±8.9	0.048
Pulse pressure	47.7±7.9	51.1±9.5	0.0003
Daytime heart rate (bpm)	79.1±10.6	76.6±10.6	0.016
Night-time blood pressure (mm Hg)			
Systolic	108.5±12.2	113.5±14.4	0.0005
Diastolic	62.5±8.5	65.3±10.1	0.0058
Pulse pressure	46.0±7.8	48.2±8.9	0.011
Night-time heart rate (bpm)	63.7±8.9	62.4±9.7	0.15

Values are arithmetic mean±SD or median (10%–90% percentiles). P-values are for differences between two groups.

\*Average of five blood pressure readings obtained at one home visit.

ABPM, ambulatory blood pressure; AF, atrial fibrillation; CV, cardiovascular.

on each subject's medical history, smoking and drinking habits and intake of medications. Diabetes mellitus was a self-reported diagnosis, or use of antidiabetic agents, or a *fasting* blood glucose concentration of at least 7.0 mmol/L. In all subjects, standard supine 12-lead resting ECGs were obtained at baseline and at each follow-up visit.

### AF ascertainment

We ascertained vital status and the incidence of fatal and non-fatal diseases from the appropriate sources in each country, as described elsewhere.<sup>14</sup> We obtained the International Classification of Disease codes for the immediate and underlying cause of death. The diagnosis of sustained or paroxysmal AF was based on the medical records of general practitioners and in the regional hospitals and on ECG obtained at the baseline and follow-up visits. Each ECG was evaluated for the presence of AF by two cardiologists independently. The incidence date of AF was defined as the date of the first ECG showing AF or the date of the first hospital record or standardised questionnaire reporting a confirmed AF diagnosis.

### Statistical methods

For database management and statistical analysis, we used SAS software V.9.4. We compared means and proportions by means of a large sample z-test and the  $\chi^2$  test, respectively.

We first calculated the incidence of AF events according to cross-classification of conventional and daytime BP and quartile of daytime systolic pressure load while standardising for sex and age (age groups: <40 years, 40–60 years and >60 years) by the direct method. We used Cox regression to compute standardised HRs, which express the risk associated with a 1 SD increment in the baseline BP measurements. All Cox regression models included cohort as a random effect. The baseline characteristics considered as covariables in Cox regression were sex, age, body mass index (BMI), smoking, drinking, serum cholesterol, antihypertensive treatment, diabetes mellitus and a history of cardiovascular disease.

In the categorical analyses, we used the Kaplan-Meier survival function estimate and the log-rank test to plot and compare the cumulative incidence of AF across quartiles of conventional systolic BP, daytime systolic BP and daytime systolic BP load. While accounting for important covariables, we also expressed

**Table 3** Conventional and 24-hour ambulatory blood pressure in the prediction of atrial fibrillation in 2776 participants with complete 24-hour ambulatory blood pressure monitoring

Blood pressure component	Conventional blood pressure		Ambulatory blood pressure					
			24-hour blood pressure		Daytime blood pressure		Night-time blood pressure	
	HRs (95% CI)	P value	HRs (95% CI)	P value	HRs (95% CI)	P value	HRs (95% CI)	P value
Systolic								
Mean±SD, mm Hg	125.8±17.1		119.3±11.4		125.6±12.1		108.7±12.3	
Adjusted	1.19 (0.99 to 1.43)	0.060	1.27 (1.07 to 1.51)	0.0056	1.22 (1.02 to 1.46)	0.023	1.20 (1.02 to 1.42)	0.029
Diastolic								
Mean±SD, mm Hg	77.9±10.9		72.1±7.7		77.8±8.3		62.6±8.6	
Adjusted	1.10 (0.90 to 1.34)	0.36	1.14 (1.03 to 1.48)	0.024	1.16 (0.96 to 1.40)	0.13	1.19 (1.01 to 1.42)	0.043
Pulse pressure								
Mean±SD, mm Hg	48.0±12.2		47.2±7.5		47.8±8.0		46.1±7.8	
Adjusted	1.17 (1.00 to 1.38)	0.050	1.18 (0.99 to 1.40)	0.060	1.16 (0.98 to 1.37)	0.073	1.12 (0.94 to 1.34)	0.19

HRs (95% CI) are for the risk associated with 1 SD increases in systolic, diastolic and mean blood pressure. All HRs were computed by Cox regression including cohort as a random effect and adjusted for sex, age, body mass index, serum cholesterol, tobacco and alcohol use, history of cardiovascular disease and diabetes mellitus and antihypertensive drug treatment.

the risk in each systolic pressure or load quartile relative to the overall risk in the whole study population.

## RESULTS

### Characteristics of participants

The 3956 subjects (mean age 43.1±15.1 years) included 2050 (51.8%) women. Of the participants, 2452 (62.0%) were normotensive, 219 (5.5%) had white-coat hypertension, 364 (9.2%) had masked hypertension, 321 (8.1%) had untreated sustained hypertension and 600 (15.1%) were on antihypertensive drug therapy. Online supplementary table S2 shows the baseline characteristics of these five groups. The whole study population consisted of 2574 Flemish (65.1%), 314 Italians (7.9%), 601 Polish (15.2%), 298 Russians (7.4%) and 174 Czechs (4.4%).

### Incidence of AF and its determinants

In the overall study population (n=3956), median follow-up was 14.0 years (5th–95th percentile interval: 5.6–25.2 years). During 58 810 person-years of follow-up, 143 participants experienced AF with a median time-to-event of 12.0 years (2.43 events per 1000 person-years). Of the 2776 subjects who underwent complete 24-hour ABP monitoring including daytime and night-time periods, 111 participants experienced AF with a median time-to-event of 12.1 years (2.76 events per 1000 person-years). Table 1 lists the clinical characteristics of participants with and without incident AF in the whole cohort and in participants with complete 24-hour BP monitoring. Overall, participants with incident AF compared with those without event were older more likely to be male and had a higher prevalence of other cardiovascular risk factors. The conventional and ABP measurements according to AF incidence are shown in table 2.

As expected the risk for AF increased across age groups: four events in participants younger than 40 years (incidence rate: 0.2/1000 person-years; number of subjects=1146), 71 events in the middle-age participants from 40 years to 65 years (3.4/1000 person-years; n=1395) and 36 events in participants older than 65 years (12.6/1000 person-years; n=235).

In addition to age, the incidence of AF increased significantly and independently with BMI (HRs for 5 kg/m<sup>2</sup>: 1.31; 95% CI 1.10 to 1.58; P=0.0028), history of cardiovascular disease (HRs: 2.54; 95% CI 1.66 to 3.87; P<0.0001) and was higher in men than in women (HRs: 1.73; 95% CI 1.21 to 2.49; P=0.0026).

We did not observe any significant association of incident AF with antihypertensive drug treatment (P=0.59).

### Risk of AF associated with conventional and ABP


The multivariate-adjusted HR (95% CI) associated with each 1 SD increase in all BP components for incident AF are shown in table 3. We stratified all analyses by cohort and adjusted for sex, age, BMI, total serum cholesterol, history of cardiovascular disease and diabetes, tobacco and alcohol use and antihypertensive drug treatment.

First, in analyses including 2776 participants with complete 24-hour ABP monitoring, the systolic BPs on 24-hour, daytime and night-time ambulatory measurement were all significant predictors of incident AF (table 3). In these models, each SD increase of systolic 24-hour, daytime and night-time BPs was associated with a 27% (P=0.0056), 22% (P=0.023) and 20% (P=0.029) increase in the risk for developing AF, respectively. Moreover, a higher diastolic BP on 24-hour ambulatory measurement was also associated with a significant increased risk for incident AF (P≤0.024; table 3). In this cohort, systolic BP on conventional measurement was only borderline associated with a 19% increased risk of AF (P=0.060; table 3). Second, in analyses including all 3956 participants with available daytime ABP our results remain similar (online supplementary table S3).

### Risk of AF associated with daytime systolic BP load

We further investigated the importance of daytime systolic ABP in predicting incidence of AF by calculating systolic BP load as the percentage BP readings above 135 mm Hg during the day. Of notice, in 766 subjects (19.4%), there were no single systolic BP readings during the day above this limit. Because of its skew distribution (online supplementary figure S1, skewness=1.19) we categorised systolic BP load into quartiles. Table 4 shows the baseline characteristics of the study participants by quartiles of daytime systolic BP load. Participants with high systolic pressure load (>38%) were older, more likely to be male and had a higher prevalence of cardiovascular risk factors, including previous cardiovascular disease, diabetes mellitus, higher BMI and total cholesterol (P<0.05 for all, table 4).

The risk for AF increased (P=0.0018 for trend) across increasing systolic BP load quartiles: from 10 in the lower quartile (sex-adjusted and age-adjusted incidence rate, 0.91/1000



**Figure 1** Cumulative incidence estimates (1-Kaplan-Meier survival estimates) for atrial fibrillation events by quartiles of conventional systolic blood pressure (SBP) (panel A), daytime systolic blood pressure (panel B) and daytime systolic blood pressure load (panel C). P values are for the differences between groups according to the log-rank test.

person-years), to 34 in the medium-low (2.47/1000 person-years) and 42 in the medium-high (2.84/1000 person-years) quartiles, to 57 in the upper quartile (3.50/1000 person-years).

Figure 1 demonstrates the Kaplan-Meier cumulative incidence of AF events in quartiles of conventional and daytime systolic BP and daytime systolic BP load (log-rank test for all P<0.0001).

**Table 4** Baseline characteristics of the study participants by quartiles of ambulatory daytime systolic blood pressure load


Characteristics	Q1 (n=953)	Q2 (n=1036)	Q3 (n=971)	Q4 (n=996)
Limits (%)	<3.2	3.2–13.7	13.8–37.9	>38.0
Incidence of AF (per 1000 person-years)*	0.91 (0.30–1.52)	2.47 (1.62–3.31) <sup>Q1</sup>	2.84 (1.98–3.71) <sup>Q1</sup>	3.50 (2.54–4.47) <sup>Q1</sup>
<b>Clinical features</b>				
Female, n (%)	684 (71.8)	568 (54.8) <sup>Q1</sup>	422 (43.5) <sup>Q1,Q2</sup>	376 (37.8) <sup>Q1,Q2,Q3</sup>
Age (year)	39.7±12.9	41.1±14.3 <sup>Q1</sup>	43.5±15.9 <sup>Q1,Q2</sup>	48.1±15.7 <sup>Q1,Q2,Q3</sup>
Body mass index (kg/m <sup>2</sup> )	24.1±4.1	25.1±4.4 <sup>Q1</sup>	25.9±4.4 <sup>Q1,Q2</sup>	27.4±4.5 <sup>Q1,Q2,Q3</sup>
Daytime heart rate (bpm)	77.8±10.7	78.1±10.9	78.5±10.9	78.5±11.0
<b>Conventional blood pressure (mm Hg)†</b>				
Systolic	113.7±10.8	119.6±12.0 <sup>Q1</sup>	126.3±12.8 <sup>Q1,Q2</sup>	140.2±17.0 <sup>Q1,Q2,Q3</sup>
Diastolic	72.4±8.6	74.7±9.2 <sup>Q1</sup>	77.7±9.6 <sup>Q1,Q2</sup>	84.4±11.7 <sup>Q1,Q2,Q3</sup>
Mean	86.1±8.2	89.7±9.2 <sup>Q1</sup>	93.9±9.4 <sup>Q1,Q2</sup>	103.0±12.0 <sup>Q1,Q2,Q3</sup>
Pulse pressure	41.4±8.3	44.8±9.2 <sup>Q1</sup>	48.6±11.0 <sup>Q1,Q2</sup>	55.9±13.8 <sup>Q1,Q2,Q3</sup>
<b>Daytime blood pressure (mm Hg)</b>				
Number of measurements/day	32±7.0	31±6.9 <sup>Q1</sup>	32±7.7 <sup>Q2</sup>	32±7.7 <sup>Q2</sup>
Systolic	113.0±5.5	119.7±4.5 <sup>Q1</sup>	127.0±3.9 <sup>Q1,Q2</sup>	140.4±8.4 <sup>Q1,Q2,Q3</sup>
Diastolic	71.4±5.5	74.6±5.4 <sup>Q1</sup>	78.4±5.9 <sup>Q1,Q2</sup>	85.3±8.1 <sup>Q1,Q2,Q3</sup>
Mean	85.1±5.1	89.2±4.6 <sup>Q1</sup>	94.2±4.8 <sup>Q1,Q2</sup>	103.2±7.6 <sup>Q1,Q2,Q3</sup>
Pulse pressure	41.7±4.9	45.1±5.3 <sup>Q1</sup>	48.6±5.9 <sup>Q1,Q2</sup>	55.1±8.2 <sup>Q1,Q2,Q3</sup>
<b>Questionnaire data</b>				
Tobacco use, n (%)	254 (26.7)	262 (25.3)	277 (28.5)	300 (30.1) <sup>Q2</sup>
Alcohol intake ≥5g/day, n (%)	193 (20.2)	264 (25.5) <sup>Q1</sup>	298 (30.7) <sup>Q1,Q2</sup>	353 (35.4) <sup>Q1,Q2,Q3</sup>
Hypertension, n (%)	98 (10.3)	167 (16.1) <sup>Q1</sup>	277 (28.5) <sup>Q1,Q2</sup>	598 (60.0) <sup>Q1,Q2,Q3</sup>
Antihypertensive treatment, n (%)	74 (7.8)	108 (10.4) <sup>Q1</sup>	157 (16.2) <sup>Q1,Q2</sup>	261 (26.2) <sup>Q1,Q2,Q3</sup>
Diabetes mellitus, n (%)	10 (1.0)	21 (2.0)	30 (3.1) <sup>Q1</sup>	63 (6.3) <sup>Q1,Q2,Q3</sup>
History of CV diseases, n (%)	56 (5.9)	69 (6.7)	88 (9.1) <sup>Q1</sup>	107 (10.7) <sup>Q1,Q2</sup>
<b>Biochemical data</b>				
Serum total cholesterol (mmol/L)	5.15±1.02	5.22±1.10	5.40±1.16 <sup>Q1,Q2</sup>	5.59±1.15 <sup>Q1,Q2,Q3</sup>

Values are arithmetic mean±SD or number of subjects (%).

\*Incidence rates were standardised for sex and age by the direct method.

†Average of five blood pressure readings obtained at one home visit.

AF, atrial fibrillation; CV, cardiovascular, Q, quartile of daytime systolic pressure load; Q1, P<0.05 vs Q1; Q2, P<0.05 vs Q2; Q3, P<0.05 vs Q3.



**Figure 2** Multivariable adjusted HRs (95% CI) for atrial fibrillation in quartiles of conventional systolic blood pressure (SBP), daytime systolic blood pressure and daytime systolic blood pressure load in 3956 subjects. The HRs express the risks versus the average risk in the whole cohort (vertical line) and are adjusted for the covariables (centre, sex, age, body mass index, smoking, drinking, serum cholesterol, antihypertensive treatment, diabetes mellitus and a history of cardiovascular disease). P values are for the differences between the risk in quartiles and the population average risk.

Figure 2 shows the adjusted HR expressing the risk in each quartile compared with the average risk in the whole cohort. For daytime systolic ABP load, in the upper quartile, the risk for incident AF was significantly higher than the average risk (46%,  $P=0.0094$ ), whereas in the lower quartile, the risk was significantly lower by 51% ( $P=0.0038$ ). In the upper quartile of conventional systolic BP, the risk was higher than the average risk (37%,  $P=0.022$ ; figure 2).

## DISCUSSION

This study includes a large and comprehensive population-based assessment of both conventional and ABP monitoring on incident AF. Our principal finding is that mean, daytime and night-time systolic ABP were significant predictors of incident AF. Importantly, conventional systolic BP measured by observer at the participants' homes was only borderline associated with risk of AF events. Moreover, we observed that the risk of new-onset AF was significantly associated with systolic daytime BP load. Indeed, systolic BP load during daytime of more than 38% was associated with a significant increased risk of AF.

On a population basis, hypertension is the most common predisposing factor for incident AF.<sup>18</sup> However, one-off conventional BP measurements do not necessarily provide the complete information, in relation to the development of incident AF. In the Framingham study, Rahman *et al*<sup>10</sup> reported on longitudinal BP patterns, referred to as trajectories. The latter were more closely related to the development of AF than a single office BP measurement, especially when persistently elevated systolic BP is present (HR: 1.95;  $P=0.03$  as compared with normotensive individuals) or antihypertensive treatment is used (HR: 1.97;  $P<0.0001$ ). In the present study, we showed that ABP monitoring offered significantly incremental predictive value for incident AF, whereas

a single conventional BP was only borderline associated with new-onset AF.

To our knowledge, two relatively small studies, one in patients with hypertension and another in a general population cohort, explored new-onset AF in relation to ABP measurements. Ciaroni *et al*<sup>8</sup> reported that after minimal adjustment for age, sex and BMI, baseline 24-hour systolic BP significantly predicted incident AF (HR: 1.16 per 10 mm Hg increase; 95% CI 1.06 to 2.47;  $P<0.001$ ) in 597 treated patients with hypertension. In addition to a short follow-up period in this study (18 months) and 28 cases with AF, the authors did not provide information on the office BP measurements and daytime systolic BP. In a general population cohort consisting of 903 subjects, Perkiömäki *et al*<sup>12</sup> found that the 24-hour systolic BP predicted the occurrence of AF ( $n=91$ ) over an average of 16.4 years of follow-up (HR: 1.09 per 10 mm Hg increase;  $P=0.023$ ). The authors emphasised that this association was mainly driven by the association between incident AF and night-time systolic BP. In our study, we observed that the systolic BPs during the entire 24-hour period, daytime and night-time were all similarly associated with the incidence of AF.

Additionally, we found that systolic BP load during the day significantly predicted the new-onset AF. Systolic BP load could be easily calculated as the percentage daytime BP readings above 135 mm Hg. If this percentage exceeds ~38% of overall BP daytime readings, which is corresponded to the upper quartile of daytime systolic BP load in our population, it might be considered as a high BP load. For example, if a patient has overall 20 BP measurements during the day of which 10 recordings exceeding 135 mm Hg, the patient's systolic BP load is as high as 50%.

Overall, AF might be considered as one of the manifestations of hypertensive target organ damage. Indeed, the presence of uncontrolled hypertension as identified by ABP monitoring leads to more

damage in the heart, such as left ventricular hypertrophy, diastolic dysfunction and atrial dilatation. Indeed, a recent meta-analysis of 14 studies in 2485 subjects showed better correlation of echocardiographically measured left ventricular mass with systolic ABP as compared with its correlation with office systolic BP (0.37 vs 0.23).<sup>19</sup> Along these lines, a high prevalence of left ventricular hypertrophy (52%) was observed in 1184 patients with non-valvular AF (mean age 72±11 years; 56% men).<sup>20</sup> Doménech *et al*<sup>21</sup> reported the significant association between night-time BP and left atrial size in 48 patients with idiopathic AF. Given that ABP monitoring is associated with target organ damage in hypertension<sup>19</sup> and with complications related to hypertension,<sup>11</sup> our study emphasises yet again the importance of quantification of the BP 'load' with repeated BP measures.

Our study findings might have important clinical implications in the management of AF, including the prevention of AF. Better stratification of subjects at risk for new-onset AF is a way of objectively informing treatment decisions and discreetly distributing medical care. Our observations suggest that ABP monitoring should become routine in the AF risk stratification of patients with hypertension. We also reported, for the first time, that daytime systolic BP load might provide clinically relevant prognostic information on incident AF. This finding should be confirmed in future studies addressing incident AF. Another question is whether inclusion of systolic BP load might improve AF risk stratification in patients with hypertension.

Our study must be interpreted within the context of its potential limitations. First, our present analysis was based only on European population-based cohorts and might not be representative for non-European populations. Second, due to low statistical power, we did not perform sensitivity analysis stratified by age groups particularly in the participants above 65 years in whom AF screening is recommended. Third, in our study, conventional BP was measured at the participants'

homes by trained observers. These BP readings might not be the same conventional BP measurements if they were recorded in the clinic. However, our current data on incident AF in masked hypertension supported our main results on continuous ABP measurements. Fourth, we did not exclude the effect of different types of various antihypertensive drugs over time, which may modulate AF development. Of notice, the proportion of our participants on antihypertensive treatment at baseline was only 15.2%. Finally, the diagnosis of AF was based mainly on medical records and in part on ECG recordings during the regular follow-up visits. However, systematic ECG monitoring over time was not performed.

## CONCLUSIONS

Systolic ABP is a significant predictor of incident AF in a population-based cohort. We also observed that participants with a daytime systolic BP load >38% had significantly increased risk of incident AF. Thus, effective management of BP load might be important to prevent incident AF.

## Author affiliations

<sup>1</sup>Department of Medicine, University of Padua, Padua, Italy

<sup>2</sup>Research Unit Hypertension and Cardiovascular Epidemiology, KU Leuven Department of Cardiovascular Sciences, Studies Coordinating Centre, University of Leuven, Leuven, Belgium

<sup>3</sup>First Department of Cardiology, Interventional Electrophysiology and Hypertension, Jagiellonian University Medical College, Krakow, Poland

<sup>4</sup>Faculty of Medicine, Charles University, Pilsen, Czech Republic

<sup>5</sup>Research Institute of Internal and Preventive Medicine – Branch of the Institute of Cytology and Genetics, SB RAS and Novosibirsk State Medical University, Novosibirsk, Russia

<sup>6</sup>Hypertension Unit, Department of Hypertension and Diabetology, Medical University of Gdansk, Gdańsk, Poland

<sup>7</sup>Institute of Cardiovascular Sciences, University of Birmingham, Birmingham, UK

**Acknowledgements** The list of investigators participated in the FLEMENGHO and EPOGH Study is provided in supplementary material.

**Collaborators** Belgium (Leuven) – T Kuznetsova, JA Staessen, L Thijs; Czech Republic (Pilsen and Prague) – J Filipovský, Z Marečková, J Peleška, J Seidlerová; Italy (Padua) – E Casiglia and V Tikhonoff; Poland (Kraków) – M Cwynar, J Gąsowski, T Grodzicki, K Kawecka-Jaszcz, M Kloch-Badełek, A Olszanecka, K Stolarz-Skrzypek, B Wizner, W Wojciechowska; (Gdansk) – N Gilis-Malinowska, K Kunicka, K Narkiewicz, W Sakiewicz, S Swierblewska and M Wójtowicz; Russian Federation (Novosibirsk) – T Kuznetsova, S Malyutina, Y Nikitin, A Ryabikov, and M Voevoda. Project coordinator: JA Staessen. Scientific coordinator: K Kawecka-Jaszcz. Echocardiographic study coordinator: T Kuznetsova. Steering committee: E Casiglia, J Filipovsky, K Kawecka-Jaszcz, Y Nikitin, JA Staessen. Data management committee: T Kuznetsova, JA Staessen, K Stolarz-Skrzypek, L Thijs, V Tikhonoff. Publication committee: E Casiglia, K Kawecka-Jaszcz, Y Nikitin.

**Contributors** KK-J, EC and JAS planned and coordinated the EPOGH and FLEMENGHO projects. VT, TK and LT constructed the database and did the statistical analyses. Responsibility for the integrity of the local datasets rests with: VT and EC (Mirano, Italy); TK, LT, NC and JAS (Noorderkempen, Belgium); KS-S and KK-J (Niepolomice, Poland); JS and JF (Pilsen, Czech Republic); TK and SM (Novosibirsk, Russia); and NG-M, ES and KN (Gdansk, Poland). VT, TK, LT, GYHL and JAS wrote the first draft of the paper. All authors interpreted the results and approved the final version of the manuscript.

**Funding** The European Union (grants IC15-CT98-0329-EPOGH, LSHM-CT-2006-037093, HEALTH-F4-2007-201550, HEALTH-2011-278249-EU-MASCARA, ERC Advanced Grant-2011-294713-EPLORE, HEALTH-F7-305507 HOMAGE and PoC Grant 713601-uPROPHET) supported the Studies Coordinating Centre (Leuven, Belgium) and the studies in Kraków, Mirano and Novosibirsk. The Studies Coordinating Centre also received grants from the Fonds voor Wetenschappelijk Onderzoek Vlaanderen, Ministry of the Flemish Community, Brussels, Belgium (grants G.0880.13 and G.0881.13).

**Funding** The European Union (grants IC15-CT98-0329-EPOGH, LSHM-CT-2006-037093, HEALTH-F4-2007-201550, HEALTH-2011-278249-EU-MASCARA, ERC Advanced Grant-2011-294713-EPLORE, HEALTH-F7-305507 HOMAGE and PoC Grant 713601-uPROPHET) supported the Studies Coordinating Centre

## Key messages

### What is already known on this subject?

Previous studies have shown that ambulatory blood pressure (ABP) was superior to conventional blood pressure (BP) in the prediction of cardiovascular events and risk stratification. However, data on the contribution of ABP components to the risk of developing atrial fibrillation (AF) are scarce.

### What might this study add?

Our study includes a large and comprehensive population-based assessment of both conventional and ABP monitoring on incident AF. Systolic ABP is a better predictor of incident AF as compared with conventional BP in a population-based cohort. We also observed that the risk of new-onset AF was significantly associated with systolic BP load. Indeed, systolic BP load during daytime of more than 38% was associated with a significant increased risk of AF.

### How might this impact on clinical practice?

Better stratification of subjects at risk for new-onset AF is a way of objectively informing treatment decisions and discreetly distributing medical care. Our present findings suggest that ABP monitoring should become routine in the AF risk stratification of patients with hypertension. Our study emphasises the importance of quantification of the BP 'load' with repeated BP measures.

(Leuven, Belgium) and the studies in Kraków, Mirano and Novosibirsk. The Studies Coordinating Centre also received grants from the Fonds voor Wetenschappelijk Onderzoek Vlaanderen, Ministry of the Flemish Community, Brussels, Belgium (grants G.0880.13 and G.0881.13).

**Competing interests** None declared.

**Patient consent** Obtained.

**Ethics approval** The study complies with the Declaration of Helsinki. Each local Institutional Review Board approved the study protocol. All subjects provided informed consent in writing.

**Provenance and peer review** Not commissioned; externally peer reviewed.

© Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2018. All rights reserved. No commercial use is permitted unless otherwise expressly granted.

## REFERENCES

- Chugh SS, Havmoeller R, Narayanan K, *et al.* Worldwide epidemiology of atrial fibrillation: a Global Burden of Disease 2010 Study. *Circulation* 2014;129:837–47.
- Schnabel RB, Yin X, Gona P, *et al.* 50 year trends in atrial fibrillation prevalence, incidence, risk factors, and mortality in the Framingham Heart Study: a cohort study. *Lancet* 2015;386:154–62.
- Miyasaka Y, Barnes ME, Gersh BJ, *et al.* Secular trends in incidence of atrial fibrillation in Olmsted County, Minnesota, 1980 to 2000, and implications on the projections for future prevalence. *Circulation* 2006;114:119–25.
- Lane DA, Skjøth F, Lip GYH, *et al.* Temporal trends in incidence, prevalence, and mortality of atrial fibrillation in primary care. *J Am Heart Assoc* 2017;6:e005155.
- Huxley RR, Lopez FL, Folsom AR, *et al.* Absolute and attributable risks of atrial fibrillation in relation to optimal and borderline risk factors: the Atherosclerosis Risk in Communities (ARIC) study. *Circulation* 2011;123:1501–8.
- Mitchell GF, Vasan RS, Keyes MJ, *et al.* Pulse pressure and risk of new-onset atrial fibrillation. *JAMA* 2007;297:709–15.
- Roetker NS, Chen LY, Heckbert SR, *et al.* Relation of systolic, diastolic, and pulse pressures and aortic distensibility with atrial fibrillation (from the Multi-Ethnic Study of Atherosclerosis). *Am J Cardiol* 2014;114:587–92.
- Ciaroni S, Bloch A, Lemaire MC, *et al.* Prognostic value of 24-hour ambulatory blood pressure measurement for the onset of atrial fibrillation in treated patients with essential hypertension. *Am J Cardiol* 2004;94:1566–9.
- Larstorp AC, Ariansen I, Gjesdal K, *et al.* Association of pulse pressure with new-onset atrial fibrillation in patients with hypertension and left ventricular hypertrophy: the Losartan Intervention For Endpoint (LIFE) reduction in hypertension study. *Hypertension* 2012;60:347–53.
- Rahman F, Yin X, Larson MG, *et al.* Trajectories of risk factors and risk of new-onset atrial fibrillation in the framingham heart study. *Hypertension* 2016;68:597–605.
- Hansen TW, Kikuya M, Thijs L, *et al.* Prognostic superiority of daytime ambulatory over conventional blood pressure in four populations: a meta-analysis of 7,030 individuals. *J Hypertens* 2007;25:1554–64.
- Perkiömäki JS, Nortamo S, Ylitalo A, *et al.* Ambulatory blood pressure characteristics and long-term risk for atrial fibrillation. *Am J Hypertens* 2017;30:264–70.
- Li Y, Zagato L, Kuznetsova T, *et al.* Angiotensin-converting enzyme I/D and alpha-adducin Gly460Trp polymorphisms: from angiotensin-converting enzyme activity to cardiovascular outcome. *Hypertension* 2007;49:1291–7.
- Stolarz-Skrzypek K, Kuznetsova T, Thijs L, *et al.* Fatal and nonfatal outcomes, incidence of hypertension, and blood pressure changes in relation to urinary sodium excretion. *JAMA* 2011;305:1777–85.
- Tikhonoff V, Kuznetsova T, Stolarz K, *et al.* Blood pressure phenotypes in relation to the beta-adducin C1797T polymorphism in the European Project on Genes in Hypertension (EPOGH). *Blood Press Monit* 2003;8:151–4.
- Staessen JA, Bieniaszewski L, O'Brien ET, *et al.* An epidemiological approach to ambulatory blood pressure monitoring: the Belgian Population Study. *Blood Press Monit* 1996;1:13–26.
- Mancia G, Fagard R, Narkiewicz K, *et al.* 2013 ESH/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). *J Hypertens* 2013;31:1281–357.
- Manolis AJ, Rosei EA, Coca A, *et al.* Hypertension and atrial fibrillation: diagnostic approach, prevention and treatment. Position paper of the Working Group 'Hypertension Arrhythmias and Thrombosis' of the European Society of Hypertension. *J Hypertens* 2012;30:239–52.
- Bliziotis IA, Destounis A, Stergiou GS. Home versus ambulatory and office blood pressure in predicting target organ damage in hypertension: a systematic review and meta-analysis. *J Hypertens* 2012;30:1289–99.
- Proietti M, Marra AM, Tassone EJ, *et al.* Frequency of left ventricular hypertrophy in non-valvular atrial fibrillation. *Am J Cardiol* 2015;116:877–82.
- Doménech M, Berrueto A, Molina I, *et al.* Nighttime ambulatory blood pressure is associated with atrial remodelling and neurohormonal activation in patients with idiopathic atrial fibrillation. *Rev Esp Cardiol* 2013;66:458–63.

# Ambulatory blood pressure and long-term risk for atrial fibrillation

## Supplemental Material

**SUPPLEMENTAL TABLE S1: Participation rate, enrollment and duration of follow-up.**

<b>Cohort</b>	<b>Participation Rate (%)</b>	<b>Enrollment</b>	<b>Follow-up (years)</b>
FLEMENGHO, Noorderkempen, Belgium	78	1985-2007	17.9 (8.7–25.7)
EPOGH			
Pilsen, Czech Republic	82	2000–2001	14.1 (13.8–14.4)
Mirano (Venice), Italy	73	1999–2001	13.3 (12.6–14.5)
Gdansk, Poland	90	2008–2010	5.6 (4.7–6.7)
Niepolomice, Kraków, Poland	54	1999–2008	13.4 (6.1–14.3)
Novosibirsk, Russian Federation	68	1999–2000	8.8 (8.0–9.5)

Duration of follow-up time is presented as median (5th–95th percentile interval). FLEMENGHO, Flemish Study on Environment, Genes and Health Outcomes; EPOGH, the European Project on Genes in Hypertension.

**SUPPLEMENTAL TABLE S2: Baseline characteristics of the study participants by cross-classification of conventional and ambulatory daytime blood pressures**

Characteristics	Normotension (n=2452)	White-coat HT (n=219)	Masked HT (n=364)	Untreated Sustained HT (n=321)	Treated HT (n=600)
Incidence of AF					
Number of events	55	10	11	19	48
Incidence rate per 1000 person-years*	1.98 (1.44-2.53)	2.33 (0.88-3.77)	2.54 (0.87-4.21)	3.91 (1.78-6.03) <sup>N</sup>	3.38 (2.36-4.39) <sup>N</sup>
Clinical features					
Female, n (%)	1365 (55.7)	93 (42.5) <sup>N</sup>	129 (35.4) <sup>N,W</sup>	109 (34.0) <sup>N</sup>	354 (59.0) <sup>W,M,S</sup>
Age (yr)	38.8±13.7	47.4±15.1 <sup>N</sup>	42.0±14.1 <sup>N,W</sup>	49.4±13.7 <sup>N,M</sup>	56.6±12.3 <sup>N,W,M,S</sup>
Body mass index (kg/m <sup>2</sup> )*	24.5±4.0	26.7±4.3 <sup>N</sup>	26.0±4.3 <sup>N</sup>	27.5±4.3 <sup>N,W,M</sup>	28.7±5.0 <sup>N,W,M,S</sup>
Daytime heart rate (bpm)	78.8±10.4	76.9±10.0 <sup>N</sup>	82.1±10.6 <sup>N,W</sup>	80.8±10.9 <sup>N,W</sup>	73.0±11.5 <sup>N,W,M,S</sup>
Conventional blood pressure (mm Hg) <sup>§</sup>					
Systolic	117.0±10.0	141.2±11.7 <sup>N</sup>	125.9±8.3 <sup>N,W</sup>	148.1±13.0 <sup>N,W,M</sup>	139.2±19.4 <sup>N,M,S</sup>
Diastolic	72.9±7.9	87.7±8.3 <sup>N</sup>	77.7±7.3 <sup>N,W</sup>	91.2±9.3 <sup>N,W,M</sup>	83.8±11.9 <sup>N,W,M,S</sup>
Mean	87.6±7.7	105.5±6.5 <sup>N</sup>	93.8±6.4 <sup>N,W</sup>	110.2±8.1 <sup>N,W,M</sup>	102.3±13.0 <sup>N,W,M,S</sup>
Pulse pressure	44.0±8.6	53.4±15.0 <sup>N</sup>	48.2±8.9 <sup>N,W</sup>	36.8±14.7 <sup>N,W,M</sup>	55.4±15.2 <sup>N,M</sup>
Daytime blood pressure (mm Hg)					
Systolic	119.7±7.6	125.9±6.2 <sup>N</sup>	136.2±6.2 <sup>N,W</sup>	142.6±9.8 <sup>N,W,M</sup>	131.0±13.5 <sup>N,W,M,S</sup>
Diastolic	74.1±5.6	77.6±5.3 <sup>N</sup>	85.8±5.9 <sup>N,W</sup>	88.8±7.5 <sup>N,W,M</sup>	80.1±9.3 <sup>N,W,M,S</sup>
Mean	88.8±5.6	93.5±4.6 <sup>N</sup>	101.8±4.6 <sup>N,W</sup>	106.3±7.2 <sup>N,W,M</sup>	97.4±10.0 <sup>N,W,M,S</sup>
Pulse pressure	45.6±6.2	48.3±6.4 <sup>N</sup>	50.4±8.9 <sup>N,W</sup>	53.8±9.7 <sup>N,W,M</sup>	50.9±9.6 <sup>N,W,S</sup>
Questionnaire data					
Tobacco use, n (%)	698 (28.5)	44 (20.1) <sup>N</sup>	136 (37.4) <sup>N,W</sup>	102 (31.8) <sup>M</sup>	113 (18.8) <sup>N,M,S</sup>
Alcohol intake ≥5 g/day, n (%)	638 (26.0)	66 (30.1)	135 (37.1) <sup>N</sup>	142 (44.2) <sup>N,M</sup>	127 (21.2) <sup>N,W,M,S</sup>
Diabetes mellitus, n (%)	23 (0.94)	4 (1.8)	11 (3.0) <sup>N</sup>	16 (5.0) <sup>N</sup>	70 (11.7) <sup>N,W,M,S</sup>
History of CV diseases, n (%)	93 (3.8)	18 (8.2) <sup>N</sup>	22 (6.0)	19 (5.9)	168 (28.0) <sup>N,W,M,S</sup>
Biochemical data					
Serum total cholesterol (mmol/liter)	5.16±1.10	5.53±1.12 <sup>N</sup>	5.49±1.13 <sup>N</sup>	5.69±1.07 <sup>N,M</sup>	5.73±1.09 <sup>N,W,M</sup>


Values are arithmetic means ± SD or number of subjects (%). See methods for definition of hypertension groups using conventional and ambulatory thresholds. AF, atrial fibrillation; CV, cardiovascular. Incidence rates were standardized for sex and age by the direct method. § Average of 5 blood pressure readings obtained at one home visit. <sup>N</sup>*P*<0.05 vs normotension, <sup>W</sup>*P*<0.05 vs white-coat hypertension, <sup>M</sup>*P*<0.05 vs masked hypertension, <sup>S</sup>*P*<0.05 vs sustained hypertension.

**SUPPLEMENTAL TABLE S3:** Conventional and daytime ambulatory blood pressure in the prediction of atrial fibrillation in 3956 participants with available daytime ambulatory blood pressure monitoring

Blood pressure component	Conventional blood pressure		Daytime blood pressure	
	HRs (95% CI)	<i>P</i> value	HRs (95% CI)	<i>P</i> value
<b>Systolic</b>				
Mean± SD, mmHg	125.0±16.6		125.1±11.7	
Adjusted	1.18 (1.00 – 1.37)	0.039	1.25 (1.07 – 1.45)	0.0040
<b>Diastolic</b>				
Mean± SD, mmHg	77.3±10.8		77.4±8.2	
Adjusted	1.08 (0.91 – 1.29)	0.40	1.18 (1.00 – 1.38)	0.054
<b>Pulse pressure</b>				
Mean± SD, mmHg	47.7±12.0		47.7±7.9	
Adjusted	1.11 (0.95 – 1.31)	0.16	1.12 (0.96 – 1.31)	0.15

Hazard ratios (HRs) (95% confidence interval) are for the risk associated with 1-SD increases in systolic, diastolic and mean arterial pressure and pulse pressure. All hazard ratios were computed by Cox regression including cohort as a random effect and adjusted for sex, age, body mass index, serum cholesterol, tobacco and alcohol use, history of cardiovascular disease and diabetes mellitus, and antihypertensive drug treatment. Hazard ratios for pulse pressure were additionally adjusted for mean arterial pressure. CI, confidence interval; SD, standard deviation.

**Supplemental Figure S1:** Distribution and probability plot for the daytime systolic blood pressure load.



***The following investigators participated in the EPOGH Study:***

*Belgium (Leuven)* – T. Kuznetsova, J.A. Staessen, L. Thijs; *Czech Republic (Pilsen and Prague)* – J. Filipovský, Z. Marecková, J. Peleška, J. Seidlerová; *Italy (Padua)* – E. Casiglia and V. Tikhonoff; *Poland (Kraków)* – M. Cwynar, J. Gąsowski, T. Grodzicki, K. Kawecka-Jaszcz, M. Kloch-Badełek, A. Olszanecka, K. Stolarz-Skrzypek, B. Wizner, W. Wojciechowska; *(Gdansk)* – N. Gilis-Malinowska, K. Kunicka, K. Narkiewicz, W. Sakiewicz, E. Swierblewska and M. Wójtowicz; *Russian Federation (Novosibirsk)* – T. Kuznetsova, S. Malyutina, Y. Nikitin, A. Ryabikov, and M. Voevoda.

Project coordinator: J A Staessen. Scientific coordinator: K Kawecka-Jaszcz. Echocardiographic study coordinator: T Kuznetsova. Steering committee: E Casiglia, J Filipovsky, K Kawecka-Jaszcz, Y Nikitin, J A Staessen. Data management committee: T Kuznetsova, JA Staessen, K Stolarz-Skrzypek, L Thijs, V Tikhonoff. Publication committee: E Casiglia, K Kawecka-Jaszcz, Y Nikitin.